The synapse has consistently been considered a vulnerable and critical target within
Alzheimer's disease, and synapse loss is, to date, one of the main biological correlates of …

Sleep abnormalities are widely reported in patients with Alzheimer's disease (AD) and are
linked to cognitive impairments. Sleep abnormalities could be potential biomarkers to detect …

Early and progressive dysfunctions of the dopaminergic system from the Ventral Tegmental
Area (VTA) have been described in Alzheimer's Disease (AD). During the long pre …

In Alzheimer's disease (AD) the accumulation of amyloid-β (Aβ) correlates with degradation
of cognition-relevant gamma oscillations. The gamma rhythm relies on proper neuronal …

Synapse loss and altered synaptic strength are thought to underlie cognitive impairment in
Alzheimer's disease (AD) by disrupting neural activity essential for memory. While synaptic …

A growing body of evidence has demonstrated a link between Alzheimer disease (AD) and
epilepsy. Late-onset epilepsy and epileptiform activity can precede cognitive deterioration in …

Alzheimer's disease (AD) is a severe neurodegenerative disorder caused by the
accumulation of toxic proteins, amyloid-beta (Aβ) and tau, which eventually leads to …

Alzheimer's disease (AD) is the most common form of dementia, and both the incidence of
this disease and its associated cognitive decline disproportionally effect women. While the …

The early stages of Alzheimer's disease (AD) have been linked to microcircuit dysfunction
and pathophysiological neuronal firing in several brain regions. Inhibitory GABAergic …

Background Patient-to-patient variability in the degree to which β-amyloid, tau and
neurodegeneration impact cognitive decline in Alzheimer's disease (AD) complicates …